Now the hard part

Now the hard part. Risk assets have performed strongly this year but now need the green shoots to translate into stronger hard data. There is still room for positioning adjustment to feed the rally, but expect it to turn less smooth and forceful.

Highlights:

  • Now the hard part. Risk assets have performed strongly this year but now need the green shoots to translate into stronger hard data. There is still room for positioning adjustment to feed the rally, but expect it to turn less smooth and forceful.
  • Trade talks, especially US/EU, remain a major risk, but we assume that Trump will not take any major self-defeating action ahead of the 2020 election.
  • Inflation has continued to undershoot, which is at the heart of the dovish CB stance and low bond yields. The balance of risks in the near term remains tilted towards further dovish surprises.
  • We keep a pro-risk bias, with a prudent overweight in equities, a larger one in Credit and an underweight in Govies. Our duration extension in Credit was well timed; we see residual value in long-dated Credit, as opposed to Govies.

Download the full publication below

NOW THE HARD PART

RELATED INSIGHTS

CHINA’S RECOVERY CONTINUED BUT A BIT SOFTER THAN EXPECTED
China's economic recovery continued in Q3 2020, although a bit softer than expected. Real GDP growth rose to 4.9% yoy, slightly below the Reuters consensus expectation of 5.2% yoy, but still a substantial upturn from the 3.2% yoy in Q2. On a quarterly base, growth dynamics softened to 2.7% qoq, after 11.7% qoq and -10% qoq in the two previous quarters.
Citywire video-interview with Peter Marber
Watch Peter Marber, fund manager of this global, non-directional, long/short approach to Emerging Markets debt, in a video-interview by Citywire.
COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients. Gilead Sciences has questioned the findings of the WHO study saying data appeared inconsistent.